Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
MRK US​

Merck & Co., Inc.(MRK US)

$145.27-1.971.34%Ext:$145.11-0.160.11%(Market Closed · 23:59:47 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Merck & Co., Inc. — Company Profile

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Robert Davis
Headquarters
Rahway, NJ, US
IPO Date
Jan 13, 1978
Employees
74,000
Website
www.merck.com

Key Metrics

Price
$144.30
Market Cap
$356.40B
Revenue (TTM)
$16.29B
Net Income (TTM)
$-4240000000.00
EPS (TTM)
-1.72
P/E (TTM)
39.89
P/B (TTM)
7.77
Dividend Yield
2.83%
ROE (TTM)
-9.24%
ROA (TTM)
-3.29%
Operating Margin
-11.57%
Beta
0.11

Dividends

Last Dividend
$0.85
Last Yield
0.03%

Summary

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Website
www.merck.com
Location
Rahway, NJ, US
Phone908 740 4000
Employees74,000
CEORobert Davis
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJan 13, 1978

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(3K)

Expand
  • 3/AMaraldo David R.22 Oct
  • 25-NSENotification of removal from listing15 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers13 Oct
  • 4Seidman Christine E1 Oct
  • 4Karsanbhai Surendralal Lanca1 Oct
  • 4Coe Mary Ellen1 Oct
  • 3Gupta Gaurav K1 Sep
  • 4Guindo Chirfi13 Aug
  • 144Guindo Chirfi13 Aug
  • 4Zachary Jennifer13 Aug
  • 144DeLuca Richard R.12 Aug
  • 144Zachary Jennifer12 Aug
  • 4DeLuca Richard R.12 Aug
  • 144DeLuca Richard R.11 Aug
  • 144DeLuca Richard R.10 Aug
  • 4DeLuca Richard R.10 Aug
  • 4Maraldo David R.7 Aug
  • 4Williams David Michael7 Aug
  • 4Guindo Chirfi7 Aug
  • 10-QQ2ended 30 Jun 20267 Aug

News

  • Merck & Co., Inc. $MRK Stock Position Increased by Fifth Third Wealth Advisors LLC04:24AM
  • AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?23 Oct
  • Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful23 Oct
  • Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall23 Oct
  • Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip23 Oct
  • Merck & Co., Inc. $MRK Stock Position Increased by Brookstone Capital Management23 Oct
  • Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data22 Oct
  • Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium22 Oct
  • Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium22 Oct
  • Why Is Moderna Stock Sinking Thursday?22 Oct
  • Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares22 Oct
  • Merck & Co., Inc. $MRK Stock Holdings Lowered by Cantor Fitzgerald Investment Advisors L.P.22 Oct
  • 3,507 Merck & Co., Inc. $MRK Shares Bought by Cardinal Capital Management22 Oct
  • 27,739 Merck & Co., Inc. $MRK Shares Sold by Axxcess Wealth Management LLC22 Oct
  • Merck & Co., Inc. $MRK Shares Purchased by Diversify Advisory Services LLC22 Oct
  • Merck (MRK) Laps the Stock Market: Here's Why21 Oct
  • Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors21 Oct
  • European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)21 Oct
  • 15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now20 Oct
  • Merck (MRK) Stock Dips While Market Gains: Key Facts19 Oct

Mentions in Filings

  • … observed with 56% and 66% of patients showing tumor shrinkage in Parts A and B, respectively. TACTI-002 In March 2018, we announced that we had entered into a clinical trial collaboration and supply agreement with <strong>Merck & Co., Inc.</strong>, Kenilworth, NJ, USA (known as MSD outside the United States and Canada) to evaluate the safety and efficacy of the combination of efti and pembrolizumab (KEYTRUDA®) in a new Phase II clinical trial (TACTI-002) for 2 …
    IMMUTEP LtdMerck & Co., Inc.·20-F - Annual report (foreign private issuer) FY 2026·FY26·23 Oct
  • … vanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology. In the first two-years, patients received EVX-01 in combination with MSD’s (<strong>Merck & Co., Inc.</strong>, Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Six out of 12 responders continued …
    Evaxion A/SMerck & Co., Inc.·EX-99.1 - 6-K - PRESS RELEASE·Q4 26·23 Oct
  • … certain cancers. He also served as President, Global Strategy Group, at Samsung Group, a multinational conglomerate, from February 2015 to February 2021. Prior to Samsung, Mr. Do served as chief strategy officer for <strong>Merck & Co., Inc.</strong>, Tyco Electronics, and Lenovo. Previous to that, he was a director and senior partner at McKinsey & Company, where he spent 17 years in the healthcare, high tech and corporate finance practices. He received a B.A. fr …
    ZincFive, Inc.Merck & Co., Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·21 Oct
  • … to that, Dr. Nicholson served on the board of directors of NodThera Limited from April 2019 until December 2021. Dr. Nicholson most recently served as CEO at Nimbus Therapeutics, LLC and previously spent 25 years at <strong>Merck & Co., Inc.</strong>, where he held strategic, leadership and operational roles across diverse therapeutic areas including inflammation, immunology and neurosciences. Dr. Nicholson began his professional career as a senior research biolo …
    Rezera Inc.Merck & Co., Inc.·S-1 - Registration statement (general form)·Q4 26·21 Oct
  • … tee of Soleno Therapeutics, Inc. from October 2025 until its acquisition by Neurocrine in May 2026. Mr. Hahn previously served as Chief Financial Officer of Verona Pharma PLC from March 2020 until its acquisition by <strong>Merck & Co., Inc.</strong> in October 2025. From January 2018 until its acquisition by Swedish Orphan Biovitrum (Sobi) in November 2019, Mr. Hahn served as Chief Financial Officer of Dova Pharmaceuticals. From 2010 until its acquisition by Mel …
    Fulcrum Therapeutics, Inc.Merck & Co., Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·20 Oct
  • … | | | | --- | --- | | (1) | Based solely on information obtained from a Schedule 13G filed with the SEC on December 23, 2024 by <strong>Merck & Co., Inc.</strong> (“Merck & Co.”) and Merck Sharp & Dohme LLC (“MSD”). Merck & Co. and MSD are the beneficial owners of 14,044,943 shares of Personalis Common Stock and have shared voting power and shared dispositive power over 14,044,943 shares of Personalis Common Stock. The Schedule 13G filed by Merck & Co. and MSD pr …
    Personalis, Inc.Merck & Co., Inc.·DEFM14A - Definitive proxy statement (merger)·Q4 26·21 Oct

Key Stats

Trading

Px/Chg 1D$144.30 / +0.34%
Avg Volume10.25M
Beta0.11
Mkt Cap356.40B
FD Mkt Cap364.40B

Float

Shrs Out/Float2.47B / 2.47B
Short Float0.01%
Days to Cover2.30
Stock Repurchased$874.00M

Current Valuation

EV400.24B
EV/EBITDA20.18
EV/Sales6.10
P/B7.77
P/S5.43
FCF Yield0.82%
ROE-9.24%
ROA-3.29%
Current Ratio1.30

Dividend

Cash$0.85
Yield2.83%
Yield (TTM)2.83%

Estimates

P/E39.89
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings191.7120.47916.1412.3293.67-84.06
Price / Sales10.555.015.563.2917.0021.88
Price / Book Value6.596.468.904.555.287.77
Price / Free Cash Flow68.4720.2136.5711.65152.17121.76
ENTERPRISE VALUE METRICS
Enterprise Value326,026.1316,538.8363,873.2235,901.3313,579.1400,238.0
Enterprise Value / Sales11.775.346.053.6819.2124.58
Enterprise Value / EBITDA-14.2914.8552.689.1849.80-197.94
Enterprise Value / EBIT23.5618.19119.8911.1281.85-113.25

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue7.5%48,704.059,283.060,115.064,168.064,926.0
Gross Income7.4%35,078.041,872.043,989.048,975.046,731.0
EBITDA12.1%17,899.021,315.06,907.025,706.028,262.0
EBIT11.2%14,685.017,406.03,035.021,207.022,424.0
Net Income8.8%13,049.014,519.0365.017,117.018,254.0
EPS (Diluted)9.1%5.145.710.146.747.28
BALANCE SHEET
Cash & ST Inv15.8%8,096.013,192.07,093.013,689.014,565.0
Total Assets6.7%105,694.0109,160.0106,675.0117,106.0136,866.0
Total Liabilities5.7%67,437.063,102.069,040.070,734.084,204.0
Total Shareholder Equity8.3%38,184.045,991.037,581.046,313.052,606.0
CASH FLOW
Net Operating Cash Flow3.9%14,109.019,095.013,006.021,468.016,472.0
Cap Ex-1.9%-4,448.0-4,388.0-3,863.0-3,372.0-4,112.0
Free Cash Flow6.4%9,661.014,707.09,143.018,096.012,360.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)145.05
Basic Shares2,469.82
Market Cap358,247.4
Diluted Shares2,472.00
Fully Diluted Shares Outstanding2,472.00
Fully Diluted Market Cap358,563.6
+Consolidated Debt49,117.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-5,327.0
−Short-term Investments-375.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest53.0
+Pension Liabilities—
Enterprise Value402,090.4

Segment data

Revenue

by Products and services

  • Pharmaceutical Segment89%
  • Animal Health Segment10%
  • Other Segments1%

Revenue

by Geography

  • United States56%
  • Emea22%
  • Latin America5%
  • Asia Pacific5%
  • International4%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US